PTC Therapeutics Inc
PTCT
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.13B
Close$
$29.89
56.5% downside
Current Fair Value
56.5% downsideOvervalued by 56.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $6.13 Billion |
|---|---|
| Enterprise Value | $5.69 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.58 |
| Beta | 0.53 |
| Outstanding Shares | 82,521,023 |
Return
| Return on Equity | 103.47% |
|---|---|
| Return on Assets | -6.51% |
| Return on Invested Capital | -3.70% |
Valuation & Multiples
| P/E Ratio | -32.64 |
|---|---|
| PEG | 32.53 |
| Price to Sales | 6.87 |
| Price to Book Ratio | -22.89 |
| Enterprise Value to Revenue | 6.88 |
| Enterprise Value to EBIT | -79.04 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -2.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.45
Average shareholder expectationRevenue Estimate
$217.42 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$0.28
Average shareholder expectationRevenue Estimate
$290.97 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.1743▼ 56.88% |
|---|---|
| Total Calls | 799,900▲ 201.39% |
| Total Puts | 139,400▼ 29.31% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 118.35%▲ 4.59% |
|---|---|
| Total Invested | $6.52B▼ 7.39% |
| Investors Holding | 358▼ 5.00% |
ESG Score
No data
About PTC Therapeutics Inc
CEO: Stuart Peltz